Ghassab-Abdollahi Nafiseh, Mirghafourvand Mojgan, Osouli Tabrizi Shirin
a Department of Midwifery, Faculty of Nursing and Midwifery , Students' Research Committee , Tabriz University of Medical Sciences , Tabriz , Iran.
b Social Determinants of Health Research Center, Tabriz University of Medical Sciences , Tabriz , Iran.
Eur J Contracept Reprod Health Care. 2019 Feb;24(1):71-79. doi: 10.1080/13625187.2018.1564816. Epub 2019 Feb 7.
We carried out a systematic review of the literature to evaluate the effect of centchroman on mastalgia as well as any side effects.
The databases of the Cochrane Library, Medline (PubMed), Embase, ProQuest and ClinicalTrials.gov were systematically searched. The quality of randomised controlled clinical trials (RCTs) was assessed using the Cochrane Collaboration's tool for assessing risk of bias in randomised clinical trials. The quality of non-randomised clinical trials was assessed using the Cochrane risk of bias assessment tool for non-randomised studies of interventions (ROBINS-I). Owing to different outcomes reporting, a meta-analysis of the results was not possible.
Thirteen papers were included in the study. Of these, 12 showed a significant effect of centchroman in reducing breast pain at 3 months. One study that compared the effect of centchroman with that of tamoxifen reported a significant reduction in breast pain in both groups at 3 months; the difference between the two groups was not significant. Six studies showed the effectiveness of centchroman at 6 months. None of the papers reported any serious side effects of centchroman.
Since a meta-analysis could not be conducted and the quality of the papers was low, there was insufficient evidence to evaluate the effect of centchroman on mastalgia. It is therefore recommended to conduct well-designed RCTs to compare the effect of centchroman on mastalgia with that of a placebo or other medication.
我们对文献进行了系统综述,以评估炔诺酮对乳房疼痛的影响以及任何副作用。
系统检索了Cochrane图书馆、Medline(PubMed)、Embase、ProQuest和ClinicalTrials.gov数据库。使用Cochrane协作网评估随机临床试验偏倚风险的工具评估随机对照临床试验(RCT)的质量。使用Cochrane干预性非随机研究偏倚风险评估工具(ROBINS-I)评估非随机临床试验的质量。由于结果报告不同,无法对结果进行荟萃分析。
该研究纳入了13篇论文。其中,12篇显示炔诺酮在3个月时对减轻乳房疼痛有显著效果。一项比较炔诺酮与他莫昔芬效果的研究报告称,两组在3个月时乳房疼痛均显著减轻;两组之间的差异不显著。6项研究显示炔诺酮在6个月时有效。没有论文报告炔诺酮有任何严重副作用。
由于无法进行荟萃分析且论文质量较低,没有足够的证据评估炔诺酮对乳房疼痛的影响。因此,建议进行设计良好的随机对照试验,以比较炔诺酮与安慰剂或其他药物对乳房疼痛的影响。